John F. Gilmer

2.0k total citations
68 papers, 1.7k citations indexed

About

John F. Gilmer is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, John F. Gilmer has authored 68 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 21 papers in Pharmacology and 16 papers in Oncology. Recurrent topics in John F. Gilmer's work include Cholinesterase and Neurodegenerative Diseases (12 papers), Computational Drug Discovery Methods (10 papers) and Protease and Inhibitor Mechanisms (9 papers). John F. Gilmer is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (12 papers), Computational Drug Discovery Methods (10 papers) and Protease and Inhibitor Mechanisms (9 papers). John F. Gilmer collaborates with scholars based in Ireland, Canada and United States. John F. Gilmer's co-authors include Carlos Medina, Shane O’Sullivan, John M. Clancy, Ana Luı́sa Simplı́cio, Marek W. Radomski, John Walsh, Aideen Long, Ruchika Sharma, Justin J. Perry and Anthony P. Davis and has published in prestigious journals such as The Journal of Physiology, Biochemical Journal and International Journal of Molecular Sciences.

In The Last Decade

John F. Gilmer

68 papers receiving 1.6k citations

Peers

Countries citing papers authored by John F. Gilmer

Since Specialization

Citations

This map shows the geographic impact of John F. Gilmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Gilmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Gilmer more than expected).

Fields of papers citing papers by John F. Gilmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Gilmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Gilmer. The network helps show where John F. Gilmer may publish in the future.

Co-authorship network of co-authors of John F. Gilmer

This figure shows the co-authorship network connecting the top 25 collaborators of John F. Gilmer. A scholar is included among the top collaborators of John F. Gilmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. Gilmer. John F. Gilmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chimeric Antigen Receptor‐T (CAR‐T) Cells as “Living Drugs”: A Clinical Pharmacist Perspective 2024 ·Journal of Clinical Pharmacy and Therapeutics ·(unknown), (unknown), (unknown), Christopher L. Bacon, (unknown), John F. Gilmer, Athanasios Mantalaris, Nicki Panoskaltsis	1
2	Deoxycholic acid induces proinflammatory cytokine production by model oesophageal cells via lipid rafts 2021 ·The Journal of Steroid Biochemistry and Molecular Biology ·(unknown), Michael Freeley, (unknown), John F. Gilmer, Aideen Long	11
3	High Content Imaging of Barrett’s-Associated High-Grade Dysplasia Cells After siRNA Library Screening Reveals Acid-Responsive Regulators of Cellular Transitions 2020 ·Cellular and Molecular Gastroenterology and Hepatology ·(unknown), (unknown), (unknown), James D. Johnson, John F. Gilmer, Aideen Long, Dermot Kelleher, Shane P. Duggan	3
4	Novel Iron-Whey Protein Microspheres Protect Gut Epithelial Cells from Iron-Related Oxidative Stress and Damage and Improve Iron Absorption in Fasting Adults 2017 ·Acta Haematologica ·Jun Wang, Gábor Radics, (unknown), (unknown), Anne Marie Healy, John F. Gilmer, Mark Ledwidge	10
5	Nitric oxide-matrix metaloproteinase-9 interactions: Biological and pharmacological significance 2013 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Shane O’Sullivan, Carlos Medina, Mark Ledwidge, Marek W. Radomski, John F. Gilmer	93
6	A Methodology for Detection and Quantification of Esterase Activity 2013 ·Methods in molecular biology ·Ana Luı́sa Simplı́cio, Ana S. Coroadinha, John F. Gilmer, (unknown)	10
7	Azo-reductase activated budesodine prodrugs for colon targeting 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Kinga Kędziora, Mary K. O’Reilly, (unknown), Brian Keogh, Henry J. Windle, Dermot Kelleher, John F. Gilmer	16
8	New fluorescent bile acids: Synthesis, chemical characterization, and disastereoselective uptake by Caco-2 cells of 3-deoxy 3-NBD-amino deoxycholic and ursodeoxycholic acid 2012 ·Bioorganic & Medicinal Chemistry ·(unknown), Johanna J. Salomon, Ruchika Sharma, (unknown), (unknown), (unknown), Aideen Long, Jun Wang, Carsten Ehrhardt, John F. Gilmer	19
9	In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: Is this a new immediate-release therapeutic option for niacin? 2012 ·Atherosclerosis ·Mark Ledwidge, (unknown), David Kerins, Damian P. O’Connell, (unknown), (unknown), Michael P. Jones, John F. Gilmer	2
10	Structure requirements for anaerobe processing of azo compounds: Implications for prodrug design 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Kinga Kędziora, Henry J. Windle, Dermot Kelleher, John F. Gilmer	10
11	Advances in Bile Acid Medicinal Chemistry 2011 ·Current Medicinal Chemistry ·Ruchika Sharma, Aideen Long, John F. Gilmer	53
12	N-Substituted homopiperazine barbiturates as gelatinase inhibitors 2011 ·Bioorganic & Medicinal Chemistry ·(unknown), Carlos Medina, Marek W. Radomski, John F. Gilmer	45
13	A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors 2011 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Kinga Kędziora, Brian Keogh, (unknown), Mary M. Reilly, Henry J. Windle, Dermot Kelleher, John F. Gilmer	16
14	The aqueous stability of bupropion 2010 ·Journal of Pharmaceutical and Biomedical Analysis ·Paul M. O’Byrne, Robert B. Williams, John Walsh, John F. Gilmer	26
15	Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability 2010 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), Sheila A. Ryder, Juan F. Marquez, (unknown), John F. Gilmer	16
16	Novel isosorbide di-ester compounds as inhibitors of acetylcholinesterase 2008 ·Chemico-Biological Interactions ·(unknown), (unknown), (unknown), (unknown), Sheila A. Ryder, (unknown), John F. Gilmer	4
17	Novel isosorbide-based substrates for human butyrylcholinesterase 2005 ·Chemico-Biological Interactions ·John F. Gilmer, (unknown), (unknown), (unknown), (unknown), (unknown)	9
18	The Medicinal Chemistry Implications of the Anticancer Effects of Aspirin and Other NSAIDs 2003 ·Mini-Reviews in Medicinal Chemistry ·(unknown), John F. Gilmer	14
19	Isosorbide-based aspirin prodrugs 2002 ·European Journal of Pharmaceutical Sciences ·John F. Gilmer, (unknown), (unknown), John M. Clancy	32
20	Synthesis, hydrolysis kinetics and anti-platelet effects of isosorbide mononitrate derivatives of aspirin 2001 ·European Journal of Pharmaceutical Sciences ·John F. Gilmer, (unknown), (unknown), John M. Clancy	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact